1. Analyst View
2. Research Methodology
3. Market Overview
4. Industry Performance and Forecast to 2013
4.1 Branded vs Generics
4.2 Generics Drugs Market
4.2.1 By Value
4.2.2 By Volume
5. Market Potential of Generics Drugs in Key Therapies Segments
5.1 Lipid Regulators
5.2 Antipsychotics
5.3 Angiotensin II Receptor
5.4 Anti Depressants
5.5 Human Insulin
5.6 Proton Pump Inhibitors
5.7 Erythropoietin
6. Regulatory Environment
6.1 Drug Efficacy Study Implementation (DESI) Program
6.2 Hatch-Waxman Act
6.3 Patent Infringement Litigations
6.4 Para IV & the 180-day Marketing Exclusivity
6.5 FDA Requirements
6.6 Generic Initiative for Value & Efficiency (GIVE)
6.7 Healthcare Bill 2010
6.8 Ban on “Pay for delay” Settlements
6.9 Patient Protection and Affordable Care Act
7. Emerging Market Trends
7.1 Biogenerics/Biosimilar
7.2 Anti-counterfeit Coalition
7.3 Injectable Generics
7.4 Patent Expiration
7.5 Asthma & COPD Drugs
8. Key Players
8.1 Teva Pharmaceuticals USA
8.2 Watson Pharmaceuticals, Inc.
8.3 Mylan Laboratories Inc.
8.4 Pfizer Inc.
8.5 Sandoz Inc. (Novartis)
